Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
61 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
NicOx S.A. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'NicOx S.A. - Product Pipeline Review - 2016', provides an overview of the NicOx S.A.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by NicOx S.A., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of NicOx S.A. - The report provides overview of NicOx S.A. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses NicOx S.A.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features NicOx S.A.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons to buy - Evaluate NicOx S.A.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for NicOx S.A. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding NicOx S.A.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 NicOx S.A. Snapshot 6 NicOx S.A. Overview 6 Key Information 6 Key Facts 6 NicOx S.A. - Research and Development Overview 7 Key Therapeutic Areas 7 NicOx S.A. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Partnered Products 12 Partnered Products/Combination Treatment Modalities 13 NicOx S.A. - Pipeline Products Glance 14 NicOx S.A. - Late Stage Pipeline Products 14 Pre-Registration Products/Combination Treatment Modalities 14 Filing rejected/Withdrawn Products/Combination Treatment Modalities 15 Phase III Products/Combination Treatment Modalities 16 NicOx S.A. - Clinical Stage Pipeline Products 17 Phase I Products/Combination Treatment Modalities 17 NicOx S.A. - Early Stage Pipeline Products 18 Preclinical Products/Combination Treatment Modalities 18 NicOx S.A. - Drug Profiles 19 cetirizine hydrochloride 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 naproxcinod 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 azithromycin 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 bromfenac sodium 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 fluticasone propionate 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 cerdulatinib 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 ISV-405 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 NCX-1021 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 NCX-1653 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 NCX-250 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 NCX-422 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 NCX-429 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 NCX-434 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 NCX-466 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 NCX-470 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 NCX-667 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 NicOx S.A. - Pipeline Analysis 38 NicOx S.A. - Pipeline Products by Target 38 NicOx S.A. - Pipeline Products by Route of Administration 40 NicOx S.A. - Pipeline Products by Molecule Type 41 NicOx S.A. - Pipeline Products by Mechanism of Action 42 NicOx S.A. - Recent Pipeline Updates 44 NicOx S.A. - Dormant Projects 56 NicOx S.A. - Discontinued Pipeline Products 57 Discontinued Pipeline Product Profiles 57 naproxcinod 57 NCX-1000 57 NCX-1236 57 NCX-226 57 NCX-285 58 NCX-6560 58 NicOx S.A. - Locations And Subsidiaries 59 Head Office 59 Other Locations & Subsidiaries 59 Appendix 60 Methodology 60 Coverage 60 Secondary Research 60 Primary Research 60 Expert Panel Validation 60 Contact Us 60 Disclaimer 61
List of Tables
NicOx S.A., Key Information 6 NicOx S.A., Key Facts 6 NicOx S.A. - Pipeline by Indication, 2016 9 NicOx S.A. - Pipeline by Stage of Development, 2016 10 NicOx S.A. - Monotherapy Products in Pipeline, 2016 11 NicOx S.A. - Partnered Products in Pipeline, 2016 12 NicOx S.A. - Partnered Products/ Combination Treatment Modalities, 2016 13 NicOx S.A. - Pre-Registration, 2016 14 NicOx S.A. - Filing rejected/Withdrawn, 2016 15 NicOx S.A. - Phase III, 2016 16 NicOx S.A. - Phase I, 2016 17 NicOx S.A. - Preclinical, 2016 18 NicOx S.A. - Pipeline by Target, 2016 39 NicOx S.A. - Pipeline by Route of Administration, 2016 40 NicOx S.A. - Pipeline by Molecule Type, 2016 41 NicOx S.A. - Pipeline Products by Mechanism of Action, 2016 43 NicOx S.A. - Recent Pipeline Updates, 2016 44 NicOx S.A. - Dormant Developmental Projects,2016 56 NicOx S.A. - Discontinued Pipeline Products, 2016 57 NicOx S.A., Subsidiaries 59
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.